Blood plasma fractionation refers to various components of blood plasma, which are obtained via blood fractionation. Blood plasma is the type of liquid component which is composed of whole blood and makes upto nearly 55% of the total blood volume. The process such as separation, extraction, and purification of these proteins from the plasma is called as fractionation process. Plasma fractionators play a very important role in the treatment of rare life-threatening conditions. Plasma contains thousands of different proteins, however, only about 20 of these can be are used to produce therapeutic plasma products. Plasma fractionation process is based upon different criteria including their physical, solubility, and chemical conditions such as ionic strengths, temperature, and many others.

There are two three of plasma fractionation commercially available namely; albumin, immune globulin, and coagulation factor. The demand for coagulation factor plasma fractionation is high due to application in various therapeutic areas, increasing prevalence of respiratory diseases, and product developments. By application, the market is divided into immunity, therapy, surgery, and others. Therapy application is dominating owing to increasing incidences of chronic diseases across the globe and increasing diagnosis of the Von Willebrand disease.

Based on regions, the market has been analyzed across North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Among these regions, there is high adoption rate of plasma fractionation in the North America region, due to increasing per capita healthcare spending, rising demand from patients for better and advanced healthcare facilities in countries such as the US. The market in the Asia Pacific is estimated to witness the highest growth rate, owing to increasing prevalence as well as incidences of hemophilia among countries such as China and India coupled with the increasing number of the elderly population.

Some major players in the market are launching the new technically advanced product in order to increase its geographic footprint and expand its customer base.

  • In September 2018, Grifols, S.A, which is a Spain-based pharmaceutical and chemical company launched GamaSTAN immune globulin for hepatitis A virus and measles post-exposure prophylaxis.
  • In August 2018, Grifols, S.A acquired Biotest Corporation, which is the US-based company in order to expand its plasma collection network with the addition of twenty-four Biotest centers in the US
  • In February 2018, Guizhou Taibang Biological Products Co. Ltd., which is a China-based company received approval from the Hainan Provincial Health and Family Planning Commission in order to build a new plasma collection station.

Some of the key players profiled in the global plasma fractionation market report include, BPL, CSL, Kedrion, Grifols, Baxte, RAAS, Octapharma, CBOP, Hualan Bio, and Mitsubishi Tanabe.